THE EFFECT OF SACUBITRIL/VALSARTAN COMBINED WITH METOPROLOL SUCCINATE SUSTAINED-RELEASE TABLET ON CARDIAC FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE

Coronary artery disease (CAD) with heart failure (HF) is a common clinical condition.This study aimed to assess the effects of sacubitril/valsartan combined with metoprolol succinate extended-release tablets on cardiac function (CF) in patients with CAD and HF.A retrospective analysis of patients admitted between January 2018 and December 2020 was conducted.Patients were divided into two groups: an observation (Obs) group treated with sacubitril/valsartan and metoprolol succinate, and a control (Ctrl) group treated with metoprolol succinate alone.ECG parameters, vascular endothelial function (VEF), CF indicators, oxidative stress markers and clinical efficacy (CE) were compared.The Obs group showed significant improvements in left ventricular ejection fraction (LVEF), reduced left ventricular end-diastolic diameter (LVEDD) and lower levels of angiotensin II, sVCAM-1 and sICAM-1.Plasma nitric oxide (NO) levels increased, and cardiac biomarkers like NT-proBNP and cardiac troponin I (cTnI) decreased in the Obs group.The 6-minute walk test (6MWT) and oxidative stress markers (SOD, GPx) also improved.Overall, the Obs group had better CF, VEF and CE, with no significant difference in adverse events between the two groups.Sacubitril/valsartan combined with metoprolol shows potential benefits in managing CAD and HF. RezumatBoala coronarian (BC) asociat cu insuficiena cardiac (IC) reprezint o afeciune clinic comun.Studiul a avut ca scop evaluarea efectelor combinaiei dintre sacubitril/valsartan i comprimatele cu eliberare prelungit de metoprolol succinat asupra funciei cardiace (FC) la pacienii cu BC i IC.A fost realizat o analiz retrospectiv ce a cuprins pacieni internai ntre ianuarie 2018 i decembrie 2020, ce au fost mprii n dou grupuri: un grup de observaie (Obs) tratat cu sacubitril/valsartan i metoprolol succinat i un grup de control (Ctrl) tratat doar cu metoprolol succinat.Au fost evaluai parametrii EKG, funcia endotelial vascular (FEV), indicatorii funciei cardiace, markerii de stres oxidativ i eficacitatea clinic (EC), n cele dou grupuri.Grupul Obs a prezentat mbuntiri semnificative ale fraciei de ejecie a ventriculului stng (FEVS), reducerea diametrului telediastolic al ventriculului stng (DTDVS) i niveluri mai sczute de angiotensin II, sVCAM-1 i sICAM-1.Nivelurile de oxid nitric (NO) plasmatic au crescut, iar biomarkerii cardiaci precum NT-proBNP i troponina cardiac I (cTnI) au sczut n grupul Obs.Testul de mers de 6 minute (6MWT) i markerii de stres oxidativ (SOD, GPx) au artat, de asemenea, mbuntiri.n general, grupul Obs a avut o FC, FEV i EC mai bune, fr diferene semnificative n evenimentele adverse ntre cele dou grupuri.Combinaia sacubitril/valsartan i metoprolol arat beneficii poteniale n gestionarea BC i IC.